ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1719

Pandemic-Associated Complications in Pregnant Women with Rheumatic Diseases

Diana Johnson, Hiral Dave, Yunjun Luo and Christina Chambers, University of California San Diego, La Jolla, CA

Meeting: ACR Convergence 2021

Keywords: autoimmune diseases, COVID-19, pregnancy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Reproductive Issues in Rheumatic Disorders Poster (1711–1731)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Pregnant women with rheumatic diseases may have been particularly vulnerable to the various consequences of the current pandemic, whether or not they were infected with SARS-CoV-2. Some of these consequences include increased stress, anxiety and depression, substance use, and reduced compliance with prenatal care, all of which could negatively impact pregnancy outcome. In addition, comorbidities may present increased risk of infection in women with underlying rheumatic diseases.

Methods: As part of the ongoing OTIS/MotherToBaby Autoimmune Diseases in Pregnancy Project, between February, 2017, and February, 2021, 382 pregnant women with rheumatic diseases were enrolled. The study assessed comorbidities, administered standardized measures of stress (PSS-10), anxiety (STAI state and trait) and depression (EPDS) mid-gestation or at enrollment if later than mid-gestation, captured maternal report of recreational substances used anytime in pregnancy, as well as compliance with routine prenatal care procedures such as ultrasound scans for structure and screening for gestational diabetes. From the onset of the pandemic, COVID-19 test positive status at any time in pregnancy was assessed. Those enrolled in the pre-pandemic period (N = 261) were compared to those enrolled in the pandemic year (N = 121), stratified by COVID-19 test positivity in pregnancy.

Results: As shown in the Table, compared to the pre-pandemic period, pregnant women with rheumatic diseases were more likely to screen positive on state or trait anxiety. Screening positive on stress or depression was more common in those women who were infected compared to other groups, but not significantly so. Similarly, alcohol use was increased only among those with rheumatic diseases in the pandemic year who tested positive for COVID-19 in pregnancy. Pregnant women with rheumatic diseases who had a pre-pregnancy body mass index in the obese range (≥30) were significantly more likely to test positive for the virus in the pandemic year.

Conclusion: These data suggest that pregnant women with rheumatic diseases were particularly vulnerable during the pandemic year to complications that could influence pregnancy outcome.

Table. Characteristics of pregnant women with rheumatic diseases before and during the SARS-CoV_2 pandemic.


Disclosures: D. Johnson, None; H. Dave, None; Y. Luo, None; C. Chambers, Amgen Inc., 5, AstraZeneca, 5, Celgene, 5, GlaxoSmithKline, 5, Janssen Pharmaceuticals, 5, Pfizer, Inc., 5, Regeneron, 5, Hoffman La-Roche-Genentech, 5, Genzyme Sanofi-Aventis, 5, Takeda Pharmaceutical Company, 5, Sanofi, 5, UCB Pharma, 5, Sun Pharma Global FZE, 5, Gilead, 5, The Gerber Foundation, 5.

To cite this abstract in AMA style:

Johnson D, Dave H, Luo Y, Chambers C. Pandemic-Associated Complications in Pregnant Women with Rheumatic Diseases [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/pandemic-associated-complications-in-pregnant-women-with-rheumatic-diseases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pandemic-associated-complications-in-pregnant-women-with-rheumatic-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology